행사/교육
World Vaccine Congress Asia 2013
- 등록일2013-05-20
- 조회수4682
- 구분 국외
- 행사교육분류 행사
-
주관기관
Terrapinn Pte Ltd
-
행사장소
Grand Copthorne Waterfront Hotel - Singapore
-
행사기간
2013-06-17 ~ 2013-06-20
- 원문링크
- 첨부파일
1.pdf
World Vaccine Congress Asia 2013
Event overview
World Vaccine Congress Asia 2013 is Asia's largest vaccine event. It brings together all the major vaccine stakeholders, through pharmas, biotechs, NGOs, research institutes, regulators and CDCs to discuss latest industry trends, business strategies and scientific developments in the global and Asian vaccine markets.
conference programme
18th June 2013, Tuesday
Conference Day One
08.00 Registration and refreshments
08.50 Organiser’s welcome remarks: Terrapinn Asia
08.55 Chairperson’s opening remarks
Public Health Priorities in Vaccine Development
09.00 Multi-Stakeholder Panel: Developing vaccine pipelines to address Asia’s unmet medical needs
• Driving vaccine development through multi-stakeholder support for scientific innovation
• Implementing regional initiatives to expedite vaccine development for Asia
• Overcoming challenges of vaccine development for Asia’s population
› Dr. Charung Muangchana, Director, National Vaccine Institute, Thailand› Dr. Ling Wong, Program Investment Officer, Bill & Melinda Gates Foundation, United States› Dr. S.D. Ravetkar, Executive Director, Serum Institute of India, 212/2, Hadapsar, India
Multi-Stakeholder Panel: Developing vaccine pipelines to address Asia’s unmet medical needs
09.45 Narrowing immunisation gaps in Vietnam to eliminate vaccine-preventable diseases
• Identifying diseases with the highest priority and demand for vaccines development
• Implementing state initiatives to increase uptake of under-utilized vaccines
• Accessing effective vaccines to reduce burden of vaccine-preventable diseases
› Dr. Xuan Tung Nguyen, Vice Chief, Vaccine, Biologicals and Biosafety - General Department of Preventive Medicine, Ministry of Health, Thailand
Narrowing immunisation gaps in Vietnam to eliminate vaccine-preventable diseases
10.05 Eliminating vaccine-preventable diseases in Asia: Response to vaccine security and self-reliance in Asia
• Directing R&D efforts towards realizing sustainable immunization programs for Asia to control spread of diseases
• Leveraging on Asian and ASEAN collaboration to tackle disease burdens
• Establishing quality assurance of supply of vaccines
› Dr. Charung Muangchana, Director, National Vaccine Institute, Thailand Eliminating vaccine-preventable diseases in Asia: Response to vaccine security and self-reliance in Asia
10.25 Morning refreshments, exhibition visit and academic poster showcase
Aligning Vaccine Development Strategy with Unmet Medical Needs
11.00 Innovating and introducing vaccines to solve unmet medical needs of the developing world
Aligning pipeline trial development with medical challenges of the developing world Overcoming policy and regulatory challenges of introducing vaccines to emerging marketsDeveloping key cross-regional partnerships for successful research and introduction of vaccines to emerging markets
› Claudia Dovali, Global Program Team Head, Pediatric and Specialty Vaccines Global Development, Novartis Vaccines and Diagnostics, Italy Innovating and introducing vaccines to solve unmet medical needs of the developing world
11.20 Exploring new technologies for new vaccines to address infectious diseases in Asia Implementing strategies to address current and future market needs of Asia’s vaccine market Leveraging on emerging technologies to expedite vaccine development for unmet medical needs Case studies: Successful development of safe and effective vaccines
› Frederic Ors, Vice President, Business Development, Medicago, Canada
Exploring new technologies for new vaccines to address infectious diseases in Asia
11.40 In-licensing pipeline candidates and innovative work to enhance vaccine research and portfolio in the biological space
• Merck’s licensing model and interests
• Implementing in-licensing as a strategy to develop innovative vaccines for unmet medical needs
• Assessing opportunities for external research and licensing in Asia-Pacific
› Phil Kearney, Director, Licensing and External Research, MSD, Australia
In-licensing pipeline candidates and innovative work to enhance vaccine research and portfolio in the biological space
12.00 Malaria: Innovating prophylactic vaccine pipeline for tropical infectious diseases
Reviewing the epidemiology of malaria-epidemic regions in Asia and Africa and the potential for Malaria vaccine development in Asia Presenting clinical development of BK-SE36 Phase 1b in Uganda: a blood-stage vaccine for Plasmodium falciparum malaria Implementing strategies to overcome challenges of transition to phase II trials
› Prof. Toshihiro Horii, Director, Research Center for Infectious Disease Control and International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Japan Malaria: Innovating prophylactic vaccine pipeline for tropical infectious diseases
12.30 Networking luncheon, exhibition visit and academic poster showcase
Expanding Immunisation Coverage
14.00 South East Asia: Accessing Thailand’s vaccine markets
An overview of joint venture GPO-MBP to addressing top health priorities in Thailand through vaccination Gaining insight on unique needs of Thailand’s vaccine public and private marketLeveraging on WHO-prequalification to introduce vaccines in Asia-Pacific’s vaccine market
› Patchara Kootiratrakarn, Director, Regulatory Affairs, Pharmacovigilance and Business Operations, Head Pharmacist, GPO-MBP, Thailand South East Asia: Accessing Thailand’s vaccine markets
14.20 India: Overcoming challenges in production of quality vaccines for the world
• Examining opportunities for public and private sector vaccine markets
• Ensuring regulatory compliance with safety and efficacy standards for vaccines
• Case Study: Maintaining WHO prequalification for vaccine supply to national immunization programs
› Dr. S.D. Ravetkar, Executive Director, Serum Institute of India, 212/2, Hadapsar, India
India: Overcoming challenges in production of quality vaccines for the world
14.40 Overcoming the renewed threat of smallpox
Understanding the threat of small pox deriving from terrorists to the mutation of monkeypoxOvercoming the limitations of Generation 2 Smallpox Vaccine with IMVAMUNE -the only generation 3 Smallpox vaccine Introduction of Imvamune in vaccination strategy for smallpox preparedness
› Dr. Mick Martin, Regional Director, Governmental Affairs APAC, Bavarian Nordic, Malaysia› Dr. Suebpong Sangkharomy, Retired Lietenant General, Consultant, Armed Forces Research Institute of Medical Science,Royal Thai Army, Thailand Overcoming the renewed threat of smallpox
15.10 Afternoon refreshments, exhibition visit and academic poster showcase and speed networking
Alliances and Partnerships in Driving Vaccine Development in Asia
16.00 Asian Partnership Model for Bioventure: Driving therapeutic vaccine development for unmet medical needs
• Redefining AnGes’ business and partnership strategy and R&D focus to develop innovative therapeutic vaccines
• Building a strategic partnership with BioLeaders and Vical, to develop therapeutic vaccines addressing medical needs in cancer
• Leveraging on expertise and resources in research partners to fast-track vaccine R&D programs
› Dr. Shunsuke Sami, Executive Vice President, AnGes MG, Japan
Asian Partnership Model for Bioventure: Driving therapeutic vaccine development for unmet medical needs
16.20 Academic and industrial collaboration: Developing a Td and Tdap vaccine in collaboration with Green Cross
Reviewing epidemiology of tetanus, diphtheria and pertussis in Korea and opportunities for development of Tdap vaccines Developing clinical trial strategies to minimize risk and expedite vaccine development process of Td vaccine for adults Overcoming challenges of conducting clinical studies of Td and Tdap vaccine
› Prof. Jin Han Kang, President, Biomedical Industry Institute, Catholic University of Korea, Republic Of Korea
Academic and industrial collaboration: Developing a Td and Tdap vaccine in collaboration with Green Cross
16.40 Chairman’s closing remarks
16.50 End of conference
........(계속)
☞ 자세한 내용은 내용바로가기를 이용하시기 바랍니다.